Phio Pharmaceuticals Corp. reported a net loss of $4.1 million for the quarter ending June 30, 2026, driven by escalating research and development expenses. This development underscores the company's commitment to advancing its cancer treatment candidate, PH-762, as it prepares for an FDA meeting in Q3 2026.

Key Highlights

  • Research and development costs surged to $3.1 million in Q2 2026, a staggering 187% increase from the same quarter in the prior year.
  • Phio Pharmaceuticals reported cash and cash equivalents amounting to $13.0 million as of June 30, 2026, down from $21.0 million at the end of 2025.
  • Phio Pharmaceuticals is set to seek a meeting with the FDA in Q3 2026 to discuss the next steps for PH-762 following the completion of a Phase 1b trial.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) reported a net loss of $4.1 million for the quarter ending June 30, 2026, marking a substantial increase from a $2.2 million loss in the same period last year. This loss highlights ongoing financial pressures as the company expands its clinical efforts for its lead candidate, PH-762. The loss comes despite PHIO’s share price performance, which remains down 2.8% year-to-date, reflecting broader investor caution in the healthcare sector.

A comparative anchor reveals the company’s fiscal challenges, as it previously projected an EPS of $-0.34 against expectations of $-0.24.

Increased Research Expenses

Research and development costs surged to $3.1 million in Q2 2026, a staggering 187% increase from the same quarter in the prior year. This uptick is primarily attributed to rising expenses in nonclinical toxicology studies and chemistry, manufacturing, and controls (CMC). In the first half of 2026, total R&D expenses reached $5.9 million, up 200% versus the prior period.

Such aggressive investment into R&D suggests a strategic focus on advancing PH-762, as management anticipates these expenses will continue to rise with ongoing development efforts. The significant cost escalation highlights the risks involved as the company moves closer to potential FDA interactions.

Cash Reserves Lowered

Phio Pharmaceuticals reported cash and cash equivalents amounting to $13.0 million as of June 30, 2026, down from $21.0 million at the end of 2025. Despite reduced cash reserves, management projects that existing funds will sustain operations into the second half of 2027. Ensuring adequate liquidity is critical for Phio as it navigates its ambitious clinical plans while managing the associated financial risks.

Preparing for FDA Engagement

Phio Pharmaceuticals is set to seek a meeting with the FDA in Q3 2026 to discuss the next steps for PH-762 following the completion of a Phase 1b trial. The anticipated outcomes from this engagement are important for shaping the trajectory of PH-762's development and potential market introduction. As Phase 1b data is underscored in the upcoming FDA discussions, the directions taken in these conversations could significantly influence investor sentiment and market performance as well.

What to Watch Next

Investors should keep an eye on the FDA meeting scheduled for Q3 2026, where the path forward for PH-762 will be discussed. The outcomes of this meeting may reveal the future regulatory context for the candidate, impacting both the operational strategy and financial outlook for Phio Pharmaceuticals. As the company works through its clinical advancements, continuing scrutiny of financial performance will be key in gauging overall investor confidence moving forward.

Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.